E-ISSN 2587-0831
Original Article
What is the Diagnostic Performance of 18F-FDG-PET/MRI in the Detection of Bone Metastasis in Patients with Breast Cancer?
1 Department of Radiology, Gayrettepe Florence Nightingale Hospital, İstanbul, Turkey  
Eur J Breast Health 2019; 15: 213-216
DOI: 10.5152/ejbh.2019.4885
Key Words: 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/magnetic resonance imaging (MRI), breast cancer, bone metastasis
Abstract

 

Objective: To evaluate the diagnostic performance of 18F-fluorodeoxyglucose (FDG)-positron emission tomography (PET)/magnetic resonance imaging (MRI) in the detection of bone metastasis in patients with breast cancer.

 

Materials and methods: From August 2018 to January 2019, a total of 23 patients with pathologically confirmed invasive breast cancer underwent whole-body hybrid 18F-FDG -PET/MRI for initial staging and follow-up of their malignancies. The number of the bone metastasis was recorded for each patient. The total 18F-FDG-PET/MRI protocol was compared with PET only and the contrast enhanced fused (CE) component for the detection of bone metastasis.

 

Results: Eight (26%) of 23 patients had bone metastasis. Bone metastases were dominantly localized in the spine (63%) and pelvis (25%). In terms of the total number of detected bone metastasis, there was a statistically significant difference between 18F-FDG-PET/MRI (mean 3.57; median 0; range, 0-2) and PET only component (mean 2.87; median 0; range, 0-1) (p=0.026), but no statistically significant difference was detected between 18F-FDG-PET/MRI and whole-body CE MRI (mean 3.43; median 0; range 0-2) (p=0.083). 

 

Conclusion: Whole-body hybrid 18F-FDG-PET/MRI is superior to PET component only, but no statistically significant difference between hybrid 18F-FDG-PET/MRI and whole-body CE MRI is found for the detection of bone metastasis in patients with breast cancer.

 

Cite this article as: F.Ç. What is the Diagnostic Performance of 18F-FDG-PET/MRI in the Detection of Bone Metastasis in Patients with Breast Cancer?. Eur J Breast Health 2019; 15(4): 213-216.

Key Words
Authors
All
Congresses
Author’s Corner
Survey
AVES | Copyright © 2019 Turkish Federation of Breast Diseases Associations | Latest Update: 01.10.2019